We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00714025
Recruitment Status : Completed
First Posted : July 14, 2008
Last Update Posted : January 24, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
An open-label, single arm, non-randomized, single stage phase II study. 3 phases:Baseline, treatment/duration and Follow-up. All patients will be treated with RAD001 10 mg daily dose until disease progression or unacceptable toxicity death, or discontinuation from the study, for any other reason

Condition or disease Intervention/treatment Phase
Transitional Cell Carcinoma Drug: RAD001 Phase 2

Detailed Description:

An open-label, single arm, non-randomized, single stage phase II study. Baseline phase: Baseline evaluations will be performed within 2 weeks before the first dose study drug.

Treatment phase/duration of treatment: All patients will be treated with RAD001 10mg PO daily dose until disease progression (by RECIST) or unacceptable toxicity death or discontinuation from the study for any other reason.

Follow-up phase: All patients will have a follow-up visit scheduled 28 days after the last dose of the study drug to follow for AEs and SAEs that may have occured after discontinuation from the study. Any patient who is discontinued from treatment with RAD001 for any reason other than disease progression will continue to have tumor assessments until the patient has documented disease progression or start of additional anti-tumor therapy. Central radiology review and survival data collection will be performed. After discontinuation of RAD001 all patients will be followed up for survival until the final OS analysis is performed.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-based Chemotherapy
Study Start Date : November 2008
Primary Completion Date : April 2009
Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: I
40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
Drug: RAD001
RAD001 10mg, daily, PO

Outcome Measures

Primary Outcome Measures :
  1. Primary:To evaluate the preliminary efficacy of RAD001 as monotherapy for the treatment of locally advanced or metastatic TCC. Efficacy is defined as the disease control rate at 8 weeks. [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Secondary:To evaluate the response rate, duration of response, progression-free survival and overall survival in this patient population, and further characterize the safety profile of RAD001 [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients histologically-or cytologically-confirmed locally advanced or metastatic TCC not amenable to curative surgery or radiation.
  • Patients with documented disease progression after first-line platinum based therapy
  • an interval of more than 4 weeks since last cytotoxic chemotherapy, biological therapy, surgery or radiotherapy
  • patients with at least one measurable lesion as at baseline as per RECIST criteria
  • ECOG performance status of 0-2
  • Adequate bone marrow function
  • Adequate liver function
  • Adequate renal function
  • Life expectancy more than 3 months
  • Women of child-bearing age must have a negative pregnancy test within 72 hours prior to the administration of the study treatment start
  • Signed informed consent prior to beginning protocol specific procedure
  • Age more than 18 years old

Exclusion Criteria:

  • Patients who have received more than 2 systemic treatment for their metastatic disease
  • Patients who have previously received mTOR inhibitors
  • Patients with a know hypersensitivity to RAD001 or other rapamycin or to its recipients
  • Patients with brain or leptomeningeal metastases
  • Patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent
  • Patients with a known history of HIV seropositivity
  • Patients with autoimmune hepatitis
  • patients with an active, bleeding diathesis
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • Patients who have a history of another primary malignancy more than 5 years
  • Patients who are using other investigational agents or who had received investigational drugs more than 4 weeks prior to study treatment start
  • Patients unwilling to or unable to comply with the protocol
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not acceptable.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00714025

Cliniques Universitaires St Luc-UCL
Bruxelles, Belgium, 1200
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Principal Investigator: Jean-Pascal H Machiels, MD PhD Cliniques Universitaires St Luc-UCL
More Information

Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier: NCT00714025     History of Changes
Other Study ID Numbers: UCL-ONCO 08-002
First Posted: July 14, 2008    Key Record Dates
Last Update Posted: January 24, 2012
Last Verified: January 2012

Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
Palliative treatment
advance or metastatic TCC
Failure after Platinum-based chemotherapy

Additional relevant MeSH terms:
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents